| scholarly article | Q13442814 |
| P50 | author | Amanda Ewart Toland | Q38300105 |
| P2093 | author name string | Paul R Andreassen | |
| Ava Willoughby | |||
| P2860 | cites work | Dominant Negative ATM Mutations in Breast Cancer Families | Q22066027 |
| Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention | Q26744525 | ||
| Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk | Q27008356 | ||
| Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society | Q27347760 | ||
| The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study | Q27644636 | ||
| Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers | Q28067154 | ||
| Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins | Q28085364 | ||
| Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway | Q28141324 | ||
| Exposing the MYtH about base excision repair and human inherited disease | Q28201309 | ||
| American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography | Q28295438 | ||
| ClinVar: public archive of interpretations of clinically relevant variants | Q28603051 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. | Q30238753 | ||
| Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review | Q30245191 | ||
| Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry | Q45062920 | ||
| Comparison of recommendations for screening mammography using CISNET models | Q46212925 | ||
| Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer | Q46782579 | ||
| Cancer statistics, 2018. | Q47191906 | ||
| Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants | Q47277580 | ||
| Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach | Q47397232 | ||
| Assessing Breast Cancer Risk Estimates Based on the Gail Model and Its Predictors in Qatari Women | Q47733514 | ||
| DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment | Q47864272 | ||
| Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award | Q48065999 | ||
| "The race" to clone BRCA1. | Q48081790 | ||
| Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. | Q48361014 | ||
| Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. | Q48526678 | ||
| Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance. | Q48645952 | ||
| Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. | Q48717652 | ||
| Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. | Q50210067 | ||
| A role for common genomic variants in the assessment of familial breast cancer | Q85312916 | ||
| Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? | Q90335038 | ||
| Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants | Q91057564 | ||
| Regulation and modulation of PTEN activity | Q91142779 | ||
| Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position | Q93159862 | ||
| Functional evaluation and cancer risk assessment of BRCA2 unclassified variants | Q95814860 | ||
| A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. | Q51192784 | ||
| A breast cancer prediction model incorporating familial and personal risk factors. | Q52000310 | ||
| Ten-year risk of false positive screening mammograms and clinical breast examinations. | Q52245438 | ||
| Familial communication and cascade testing among relatives of BRCA population screening participants. | Q52622723 | ||
| Population Frequency of Germline BRCA1/2 Mutations. | Q53731191 | ||
| Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement | Q54092157 | ||
| Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese. | Q55040393 | ||
| Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women | Q56900447 | ||
| A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function | Q57023947 | ||
| Validation of a genetic risk score for Arkansas women of color | Q57040851 | ||
| Impact of Advancing Technology on Diagnosis and Treatment of Breast Cancer | Q57108989 | ||
| Microcalcifications in breast cancer: From pathophysiology to diagnosis and prognosis | Q57113729 | ||
| The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% | Q57250766 | ||
| Risk of breast cancer in male BRCA2 carriers | Q57266624 | ||
| Genetic and Histopathologic Evaluation ofBRCA1andBRCA2DNA Sequence Variants of Unknown Clinical Significance | Q57306006 | ||
| Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study | Q57748350 | ||
| Screening breast magnetic resonance imaging in women with hormone replacement therapy | Q57807961 | ||
| Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations | Q57910661 | ||
| A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population | Q57918178 | ||
| Population Based Testing for Primary Prevention: A Systematic Review | Q58609596 | ||
| Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing | Q58797082 | ||
| Accurate classification of BRCA1 variants with saturation genome editing | Q59068795 | ||
| BRCA in breast cancer: ESMO Clinical Practice Guidelines | Q59274104 | ||
| Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | Q62583133 | ||
| Projecting individualized probabilities of developing breast cancer for white females who are being examined annually | Q69396132 | ||
| Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 | Q71614580 | ||
| Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction | Q72752023 | ||
| Mammography use, breast cancer stage at diagnosis, and survival among older women | Q73090590 | ||
| Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel | Q85247141 | ||
| The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium | Q38793676 | ||
| MRI screening-detected breast lesions in high-risk young women: the value of targeted second-look ultrasound and imaging-guided biopsy | Q38809247 | ||
| A polygenic risk score for breast cancer risk in a Taiwanese population. | Q38958555 | ||
| BI-RADS® fifth edition: A summary of changes | Q38993876 | ||
| National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium | Q39029462 | ||
| Breast Tomosynthesis: Practical Considerations | Q39244006 | ||
| RAS Proteins and Their Regulators in Human Disease | Q39407402 | ||
| Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States | Q39734134 | ||
| Breast cancer screening using tomosynthesis in combination with digital mammography | Q40209954 | ||
| Breast cancer risk prediction using a clinical risk model and polygenic risk score | Q40605693 | ||
| Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. | Q40633720 | ||
| Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. | Q40722655 | ||
| The WISDOM Study: breaking the deadlock in the breast cancer screening debate | Q41701590 | ||
| Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women | Q43738081 | ||
| A high-throughput functional complementation assay for classification of BRCA1 missense variants | Q44400315 | ||
| US panel rejects routine use of BRCA cancer screening in women | Q44632452 | ||
| Mammography before diagnosis among women age 80 years and older with breast cancer | Q45038556 | ||
| Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. | Q30620197 | ||
| Development and evaluation of a decision aid on mammography screening for women 75 years and older | Q33596111 | ||
| Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers | Q33614244 | ||
| Common genetic variants and modification of penetrance of BRCA2-associated breast cancer | Q33742096 | ||
| The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk | Q33784408 | ||
| Breast cancer risk assessment using genetic variants and risk factors in a Singapore Chinese population | Q33892384 | ||
| Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women | Q33965090 | ||
| Recent BRCAPRO upgrades significantly improve calibration | Q33992404 | ||
| Performance of common genetic variants in breast-cancer risk models | Q34064069 | ||
| Radiation Doses and Cancer Risks from Breast Imaging Studies | Q34132972 | ||
| Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality | Q34135443 | ||
| Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination | Q34146943 | ||
| Breast-cancer risk in families with mutations in PALB2 | Q34148873 | ||
| Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information | Q34267477 | ||
| Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. | Q34314370 | ||
| Power and predictive accuracy of polygenic risk scores. | Q34337027 | ||
| Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2 | Q34384153 | ||
| p53 in signaling checkpoint arrest or apoptosis | Q34395659 | ||
| Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology | Q34465792 | ||
| Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource | Q34480599 | ||
| Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement | Q34508652 | ||
| Increased patient concern after false-positive mammograms: clinician documentation and subsequent ambulatory visits | Q34743674 | ||
| Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results | Q34788325 | ||
| Breast cancer detection among young survivors of pediatric Hodgkin lymphoma with screening magnetic resonance imaging | Q34819549 | ||
| Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial | Q34994568 | ||
| Radiation exposure from imaging tests: is there an increased cancer risk? | Q35008997 | ||
| Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study | Q35532803 | ||
| Rare variants in the ATM gene and risk of breast cancer | Q35608690 | ||
| ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes | Q35618857 | ||
| In vivo radioadaptive response: a review of studies relevant to radiation-induced cancer risk. | Q35642728 | ||
| Genetics of breast cancer: a topic in evolution | Q35775223 | ||
| Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women | Q35846927 | ||
| The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
| Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay. | Q36190966 | ||
| SNPs and breast cancer risk prediction for African American and Hispanic women | Q36322904 | ||
| Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores | Q36356727 | ||
| Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women | Q36393157 | ||
| Breast cancer risk-assessment models | Q36458723 | ||
| A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes | Q36492194 | ||
| A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity | Q36511037 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry | Q36619329 | ||
| The BOADICEA model of genetic susceptibility to breast and ovarian cancer | Q36695832 | ||
| BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers | Q37002955 | ||
| Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2 | Q37092814 | ||
| Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance | Q37117082 | ||
| Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model | Q37172219 | ||
| Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status | Q37223335 | ||
| The cell-cell adhesion molecule E-cadherin. | Q37251750 | ||
| BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk | Q37261138 | ||
| Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations | Q37363083 | ||
| Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab | Q37410693 | ||
| Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry | Q37487782 | ||
| Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing | Q37531346 | ||
| The role of MRI in breast cancer screening | Q37636599 | ||
| Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions | Q37653428 | ||
| Functional assays for analysis of variants of uncertain significance in BRCA2. | Q37715826 | ||
| Discovering moderate-risk breast cancer susceptibility genes | Q37719902 | ||
| A short history of the genome-wide association study: where we were and where we are going | Q38076409 | ||
| Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation | Q38173683 | ||
| Mechanisms of ATM Activation | Q38314959 | ||
| Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial | Q38413461 | ||
| Population genetic testing for cancer susceptibility: founder mutations to genomes | Q38611712 | ||
| Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation | Q38693248 | ||
| Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers | Q38717239 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Risk Stratification | Q57630821 |
| P304 | page(s) | 15 | |
| P577 | publication date | 2019-03-01 | |
| P1433 | published in | Journal of personalized medicine | Q27724740 |
| P1476 | title | Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer | |
| P478 | volume | 9 |
| Q89578180 | Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program | cites work | P2860 |
Search more.